As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and confirms simufilam’s favorable safety profile in these studies Exploratory post-hoc analyses offer informative insights AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive has a presence in key finance and investing hubs with offices in London, New York, Toronto, Vancouver, Sydney, and Perth [2] Group 2 - The company utilizes technology to enhance workflows and improve content production [4] - Proactive employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5] - The editorial team produces approximately 50,000 pieces of news and feature articles annually [1]

Group 1 - Proactive Investors provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive has a history of adopting technology to enhance workflows, utilizing decades of expertise from its content creators [4] - The company employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for being a forward-looking technology adopter, utilizing decades of expertise and experience among its content creators [4] - The company employs automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Company Overview - Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines through base editing [3] - The company aims to establish a leading, fully integrated platform for precision genetic medicines, incorporating gene editing, delivery, and internal manufacturing capabilities [3] - Beam's proprietary base editing technology allows for precise, predictable, and efficient single base changes in targeted genomic sequences without causing double-stranded breaks in DNA [3] Upcoming Event - John Evans, the CEO of Beam Therapeutics, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 5:15 p.m. PT in San Francisco [1] - The live webcast of the presentation will be available on the company's investor section of the website and archived for 60 days [2]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for being a forward-looking technology adopter, utilizing decades of expertise and experience among its content creators [4] - The company employs automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for being a forward-looking technology adopter, utilizing decades of expertise and experience among its content creators [4] - The company employs automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Core Insights - The global interest in China's biopharma sector is driven by the lower costs of early clinical programs compared to the US and Europe, with expectations for increased dealmaking between China and the West as 2026 approaches [1][2] Group 1: Deal Trends and Values - There has been a significant rise in high-value deals between the West and China, with 20 transactions exceeding $500 million in 2023 alone [2] - Major deals in 2025 include Novartis's $5.36 billion agreement with Argo Biopharmaceutical, AstraZeneca's $5.3 billion deal with CSPC Pharmaceutical, and Zenas Biopharma's $2 billion agreement with InnoCare Pharma [2] - Chinese innovator drug licensing deals accounted for 28% of the innovator deals signed by large pharma in 2024, totaling $41.5 billion in value [3] Group 2: R&D and Therapeutic Focus - Western companies are increasingly seeking partnerships with Chinese biotech firms to enhance their pipelines with cost-effective therapies, particularly in oncology, immunology, and cardiometabolic health [4] - The rapid growth of China's clinical trial ecosystem has positioned the country as a leader in global study initiations in 2024 [5] - China is shifting from a reputation for generic drug manufacturing to developing innovative therapies, capturing global pharmaceutical attention [6] Group 3: Oncology and Innovative Therapies - Oncology remains a focal point for licensing agreements, with significant deals from companies like AbbVie, Pfizer, and GSK [9] - Antibody-drug conjugates (ADCs) developed in China are particularly appealing to Western dealmakers due to their innovative potential [10] - Next-generation biologics, including ADCs, bispecifics, and cell and gene therapies, are driving interest from investors and large pharmaceutical companies [11] Group 4: Future Outlook and Strategic Shifts - Immunology is expected to remain a key area of focus in 2026, alongside a rise in cardiometabolic deals targeting the obesity market [13] - The BIOSECURE Act could impact interactions between Western and Chinese companies, but industry leaders express confidence in the resilience of innovation-driven strategies [14][16] - Some Chinese companies are exploring self-commercialization strategies, although most will likely continue to rely on licensing deals in the near term due to a lack of global market experience [18][19]